Isakova et al. evaluated a large prospective cohort of patients with CKD stages 2–4, and identified that elevated FGF-23 is an independent risk factor for end-stage renal disease (ESRD) [23]. This evidence concerns the gene FGF23 and stage 5 chronic kidney disease.